| Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial.Lancet Oncol | PMID 39214106无 PMCID | 2024-Sep | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Subcutaneous efgartigimod PH20 in generalized myasthenia gravis: A phase 3 randomized noninferiority study (ADAPT-SC) and interim analyses of a long-term open-label extension study (ADAPT-SC+).Neurotherapeutics | PMID 39227284PMC11579873 | 2024-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Capivasertib and fulvestrant for patients with hormone receptor-positive advanced breast cancer: characterization, time course, and management of frequent adverse events from the phase III CAPItello-291 study.ESMO Open | PMID 39241495PMC11406080 | 2024-Sep | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| QL1701 (a proposed trastuzumab biosimilar) versus reference trastuzumab plus docetaxel as first-line therapy for HER2-positive metastatic breast cancer: a multicenter, randomized, double-blinded, parallel-controlled, phase III equivalence trial.ESMO Open | PMID 39241496PMC11406081 | 2024-Sep | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Dose Justification for Asciminib in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia with and Without the T315I Mutation.Clin Pharmacokinet | PMID 39243304PMC11450061 | 2024-Sep | 0.45 | The study is a randomized Phase III trial of a drug (asciminib) in human oncology (CML-CP) with original results. However, the primary efficacy endpoint is major molecular response rate (a categorical response rate), not a time-to-event endpoint like OS, PFS, DFS, EFS, RFS, or TTP. The abstract does not mention Kaplan-Meier analysis, hazard ratios, or any time-to-event outcome, so it fails the time-to-event criterion. | 待处理 |
| Integrated Population Pharmacokinetics of Daprodustat in Patients with Chronic Kidney Disease with Anemia.Clin Pharmacokinet | PMID 39259485无 PMCID | 2024-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Interim safety and immunogenicity analysis of the EuCorVac-19 COVID-19 vaccine in a Phase 3 randomized, observer-blind, immunobridging trial in the Philippines.J Med Virol | PMID 39318203无 PMCID | 2024-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Cemiplimab monotherapy in Japanese patients with recurrent or metastatic cervical cancer.Cancer Med | PMID 39325020PMC11426160 | 2024-Sep | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Effect of acute kidney injury and overall survival in patients with postoperative head and neck cancer who received chemoradiotherapy with cisplatin: A supplementary analysis of the phase II/III trial of JCOG1008.Cancer Med | PMID 39348265PMC11441389 | 2024-Sep | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| How do SGLT2 inhibitors protect the kidney? A mediation analysis of the EMPA-REG OUTCOME trial.Nephrol Dial Transplant | PMID 38323492PMC11361804 | 2024-Aug-30 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Implementation and adherence to regular asymptomatic testing in a COVID-19 vaccine trial.Vaccine | PMID 39060202无 PMCID | 2024-Aug-30 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Genomic imbalance analysis provides new insight into prognostic factors in adult and pediatric T-ALL.Blood | PMID 38518104无 PMCID | 2024-Aug-29 | 0.85 | The record describes a randomized phase II/III trial in oncology with human subjects and drug intervention, but the abstract does not explicitly present a time-to-event efficacy endpoint (e.g., OS, PFS) with KM or HR data; it focuses on genomic prognostic factors. | 待处理 |
| Long-term safety and effectiveness of mRNA-1273 vaccine in adults: COVE trial open-label and booster phases.Nat Commun | PMID 39209823PMC11362294 | 2024-Aug-29 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Evaluating trends in damage to attractive targeted sugar baits (ATSBs) deployed during the second year of a two-year Phase III trial in Western Zambia.Malar J | PMID 39210405PMC11363357 | 2024-Aug-29 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Exploratory analysis of the potential disconnect between objective inflammatory response and clinical response following certolizumab pegol treatment in patients with active axial spondyloarthritis.RMD Open | PMID 39209369PMC11367372 | 2024-Aug-28 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Cerebral small vessel disease modifies outcomes after minimally invasive surgery for intracerebral haemorrhage.Stroke Vasc Neurol | PMID 37949482PMC11420921 | 2024-Aug-27 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Clinical Treatment Score Post-5 Years (CTS5) and Late Recurrence Risk in Hormone Receptor-Positive, HER2-Positive Breast Cancer.J Natl Compr Canc Netw | PMID 39191270PMC11473094 | 2024-Aug-26 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial.Lancet | PMID 39181597无 PMCID | 2024-Aug-24 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Heterogeneity in disease activity, frequency of treatments, and visual outcomes among patients with retinal vein occlusion: relationship between injection need and vision with as-needed ranibizumab.Br J Ophthalmol | PMID 38290802PMC11347224 | 2024-Aug-22 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma.N Engl J Med | PMID 39167807无 PMCID | 2024-Aug-22 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Factors influencing fidelity to guideline implementation strategies for improving pain care at cancer centres: a qualitative sub-study of the Stop Cancer PAIN Trial.BMC Health Serv Res | PMID 39174979PMC11342688 | 2024-Aug-22 | 0.90 | The record describes a qualitative sub-study of a Phase III RCT evaluating implementation strategies for pain care in cancer patients. While the parent trial is oncology-related and randomized, this specific report is a qualitative analysis of factors influencing fidelity and does not report any survival, progression, recurrence, death, or other efficacy outcomes relevant to KM digitization. | 待处理 |
| Association between matrix metalloprotease-3 levels and radiographic progression in patients with rheumatoid arthritis: A post hoc analysis from a Japanese Phase 3 clinical trial of peficitinib (RAJ4).Mod Rheumatol | PMID 37902304无 PMCID | 2024-Aug-20 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Tirzepatide for Weight Reduction in Chinese Adults With Obesity: The SURMOUNT-CN Randomized Clinical Trial.JAMA | PMID 38819983PMC11337071 | 2024-Aug-20 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Adjunctive Statistical Standardization of Adjuvant Estrogen Receptor and Progesterone Receptor in Canadian Cancer Trials Group MA.27 Postmenopausal Breast Cancer Trial of Exemestane Versus Anastrozole.J Clin Oncol | PMID 38824432无 PMCID | 2024-Aug-20 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study.J Clin Oncol | PMID 38833658PMC11328923 | 2024-Aug-20 | 1.00 | 命中用户提供的消化道肿瘤阳性参考集。 | 待处理 |
| Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study.J Clin Oncol | PMID 38843511PMC11328920 | 2024-Aug-20 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Tadalafil for Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension in Patients With Heart Failure and Preserved Ejection Fraction: A Randomized Controlled Phase 3 Study.Circulation | PMID 38939948无 PMCID | 2024-Aug-20 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of abrocitinib in Chinese patients with moderate-to-severe atopic dermatitis: A post hoc analysis of the JADE REGIMEN phase 3 trial.Chin Med J (Engl) | PMID 39018121PMC11332698 | 2024-Aug-20 | 0.99 | 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 | 待处理 |
| HSD3B1 genotype and outcomes in metastatic hormone-sensitive prostate cancer with androgen deprivation therapy and enzalutamide: ARCHES.Cell Rep Med | PMID 39168093PMC11384952 | 2024-Aug-20 | 0.85 | The record describes a subgroup analysis of a Phase III trial, not the original primary result report. Therefore, it is excluded as an original formal-result report. | 待处理 |
| Ivonescimab Plus Chemotherapy in Non-Small Cell Lung Cancer With EGFR Variant: A Randomized Clinical Trial.JAMA | PMID 38820549PMC11337070 | 2024-Aug-20 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 已完成 |
| Effect of early administration of tetracosactide on mortality and host response in critically ill patients requiring rescue surgery: a sensitivity analysis of the STOPSHOCK phase 3 randomized controlled trial.Mil Med Res | PMID 39160574PMC11331742 | 2024-Aug-19 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Adverse event assessment in a parenting programme: experiences from a multisite randomised controlled trial.Trials | PMID 39154169PMC11330034 | 2024-Aug-17 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Seroreversion to Chlamydia trachomatis Pgp3 Antigen Among Children in a Hyperendemic Region of Amhara, Ethiopia.J Infect Dis | PMID 38134305PMC11326833 | 2024-Aug-16 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Interim Report of the Reactogenicity and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 XBB-Containing Vaccines.J Infect Dis | PMID 38349280PMC11326827 | 2024-Aug-16 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Onset and resolution of ovarian toxicity with nirogacestat treatment in females with desmoid tumors: Updated safety analyses from the DeFi phase 3 study.Cancer | PMID 38703010无 PMCID | 2024-Aug-15 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC.N Engl J Med | PMID 38828946无 PMCID | 2024-Aug-15 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Safety and Effectiveness From the Cabotegravir and Rilpivirine Implementation Study in European Locations Study: Phase 3b Hybrid Type III Implementation Study Integrating Cabotegravir + Rilpivirine Long-Acting Into European Clinical Settings.J Acquir Immune Defic Syndr | PMID 38985445PMC11236265 | 2024-Aug-15 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A multicentre randomized double-blind placebo-controlled phase III study of the efficacy and safety of xeligekimab (GR1501) in patients with moderate-to-severe plaque psoriasis.Br J Dermatol | PMID 38366639无 PMCID | 2024-Aug-14 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and Safety of Etrasimod in Patients with Moderately to Severely Active Isolated Proctitis: Results From the Phase 3 ELEVATE UC Clinical Programme.J Crohns Colitis | PMID 38613425PMC11324338 | 2024-Aug-14 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Factors associated with reactogenicity to an investigational HIV vaccine regimen in HIV vaccine trials network 702.Vaccine | PMID 38772835PMC11320363 | 2024-Aug-13 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy of Ofatumumab and Teriflunomide in Patients With Relapsing MS From Racial/Ethnic Minority Groups: ASCLEPIOS I/II Subgroup Analyses.Neurology | PMID 39018512PMC11314949 | 2024-Aug-13 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Gefitinib (an EGFR tyrosine kinase inhibitor) plus anlotinib (an multikinase inhibitor) for untreated, EGFR-mutated, advanced non-small cell lung cancer (FL-ALTER): a multicenter phase III trial.Signal Transduct Target Ther | PMID 39134529PMC11319491 | 2024-Aug-13 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Measuring treatment impacts on symptoms in adults with hypoparathyroidism: findings from the PaTHway trial.J Patient Rep Outcomes | PMID 39136801PMC11322464 | 2024-Aug-13 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Community acceptance of a novel malaria intervention, Attractive Targeted Sugar Baits, in the Zambia phase III trial.Malar J | PMID 39129018PMC11318112 | 2024-Aug-12 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Patient-Reported Outcomes From the Phase III HIMALAYA Study of Tremelimumab Plus Durvalumab in Unresectable Hepatocellular Carcinoma.J Clin Oncol | PMID 38805668PMC11315407 | 2024-Aug-10 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Olanzapine Plus Triple Antiemetic Therapy for the Prevention of Carboplatin-Induced Nausea and Vomiting: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial.J Clin Oncol | PMID 38833659PMC11315403 | 2024-Aug-10 | 0.95 | The trial is a randomized Phase III oncology study with a drug intervention and original results, but its primary and secondary efficacy endpoints are binary response rates (complete response, nausea-free), not time-to-event outcomes. Therefore, it does not meet the core eligibility criterion for a time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, or Kaplan-Meier/HR). | 待处理 |
| Bempegaldesleukin Plus Nivolumab Versus Sunitinib or Cabozantinib in Previously Untreated Advanced Clear Cell Renal Cell Carcinoma: A Phase III Randomized Study (PIVOT-09).J Clin Oncol | PMID 38838287无 PMCID | 2024-Aug-10 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Phase 3 Trial of Crinecerfont in Pediatric Congenital Adrenal Hyperplasia.N Engl J Med | PMID 38828945无 PMCID | 2024-Aug-08 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Phase 3 Trial of Crinecerfont in Adult Congenital Adrenal Hyperplasia.N Engl J Med | PMID 38828955PMC11309900 | 2024-Aug-08 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Pamrevlumab for Idiopathic Pulmonary Fibrosis: The ZEPHYRUS-1 Randomized Clinical Trial.JAMA | PMID 38762797PMC11304118 | 2024-Aug-06 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |